1-20 of 32
Ahmed Hamdy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Selectivity and Safety of VIP943: A Novel CD123-Targeting Antibody-Drug Conjugate (ADC) Using a Proprietary Linker and Payload Class

Beatrix Stelte-Ludwig, Tibor Schomber, Raquel Izumi, Harvey Wong, Melanie M Frigault, Anne-Sophie Rebstock, Sebastian Ludwig, Arushi Mithal, Amy J Johnson, Ahmed Hamdy
Journal: Blood
Blood (2023) 142 (Supplement 1): 1435.
https://doi.org/10.1182/blood-2023-182260
Published: 2023
Journal Articles

Targeting CDK9 in KMT2A-Rearranged Infant Leukemia: Evidence for Activity and Drug Synergy with Enitociclib

Ritul Sharma, Melanie M Frigault, Amy J Johnson, Raquel Izumi, Ahmed Hamdy, Joseph Birkett, Beatrix Stelte-Ludwig, Luke Maese, Norman J. Lacayo, Aru Narendran
Journal: Blood
Blood (2023) 142 (Supplement 1): 4293.
https://doi.org/10.1182/blood-2023-180567
Published: 2023
Journal Articles

Comparison of the CXCR5-Antibody Drug Conjugate (ADC; VIP924) to a CD19-ADC and a CD79b-ADC in a Humanized Rec-1 Mantle Cell Lymphoma (MCL) Mouse Model

Tibor Schomber, Beatrix Stelte-Ludwig, Anne-Sophie Rebstock, Oliver v Ahsen, Amy J Johnson, Raquel Izumi, Ahmed Hamdy
Journal: Blood
Blood (2023) 142 (Supplement 1): 2809.
https://doi.org/10.1182/blood-2023-182185
Published: 2023
Journal Articles

Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Mazyar Shadman, Anthony R. Mato, Connie Lee Batlevi, Ian W. Flinn, Martin Gutierrez, Marc Uemura, Don A. Stevens, Daniel Morillo, John C. Byrd, Melanie M. Frigault, George Clemens, Xin Huang, Raquel Izumi, Harvey Wong, Renee Breed, Hermes Garban, Amy J. Johnson, Beatrix Stelte-Ludwig, Arushi Mithal, Joseph Birkett, Ahmed Hamdy, Kerry A. Rogers
Journal: Blood
Blood (2022) 140 (Supplement 1): 9454–9456.
https://doi.org/10.1182/blood-2022-167651
Published: 2022
Journal Articles

VIP943 Is a Novel CD123 Antibody Drug Conjugate with in Vitro and In Vivo Efficacy in Acute Myeloid Leukemia (AML) Models

Beatrix Stelte-Ludwig, George Clemens, Tibor Schomber, Melanie M. Frigault, Amy J. Johnson, Hans-Georg Lerchen, Raquel Izumi, Ahmed Hamdy
Journal: Blood
Blood (2022) 140 (Supplement 1): 5955–5956.
https://doi.org/10.1182/blood-2022-167556
Published: 2022
Journal Articles

Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma

Son Tran, Ritul Sharma, Chunfen Zhang, Ranjan Maity, Amy J. Johnson, Melanie M. Frigault, Raquel Izumi, Ahmed Hamdy, Beatrix Stelte-Ludwig, Nizar J. Bahlis, Paola Neri, Aru Narendran
Journal: Blood
Blood (2022) 140 (Supplement 1): 10685–10686.
https://doi.org/10.1182/blood-2022-169917
Published: 2022
Journal Articles

VIP152 Is a Novel CDK9 Inhibitor with Efficacy in Chronic Lymphocytic Leukemia

Steven Sher, Larry Beaver, Katie Williams, Shelley Orwick, Brandi R. Walker, Charles Thomas Gregory, Matthew Purcell, Alexander Pan, Pearlly S. Yan, Amy J. Johnson, Melanie M. Frigault, Joy M. Greer, Ahmed Hamdy, Raquel Izumi, Stuart Hwang, James S. Blachly, John C. Byrd, Rosa Lapalombella
Journal: Blood
Blood (2021) 138 (Supplement 1): 270.
https://doi.org/10.1182/blood-2021-153812
Published: 2021
Journal Articles

VIP152, a Selective CDK9 Inhibitor, Induces Complete Regression in a High-Grade B-Cell Lymphoma (HGBL) Model and Depletion of Short-Lived Oncogenic Driver Transcripts, MYC and MCL1, with a Once Weekly Schedule

Melanie M. Frigault, Harvey Wong, Hermes Garban, Joy M. Greer, Stuart Hwang, Raquel Izumi, Amy J. Johnson, Beatrix Stelte-Ludwig, Ahmed Hamdy
Journal: Blood
Blood (2021) 138 (Supplement 1): 1192.
https://doi.org/10.1182/blood-2021-150917
Published: 2021
Journal Articles

Acalabrutinib in treatment-naive chronic lymphocytic leukemia

Clinical Trials & Observations
John C. Byrd, Jennifer A. Woyach, Richard R. Furman, Peter Martin, Susan O’Brien, Jennifer R. Brown, Deborah M. Stephens, Jacqueline C. Barrientos, Stephen Devereux, Peter Hillmen, John M. Pagel, Ahmed Hamdy, Raquel Izumi, Priti Patel, Min Hui Wang, Nitin Jain, William G. Wierda
Journal: Blood
Blood (2021) 137 (24): 3327–3338.
https://doi.org/10.1182/blood.2020009617
Published: 2021
Includes: Supplemental data
Journal Articles

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Clinical Trials & Observations
Clare Sun, Pia Nierman, Ellen K. Kendall, Jean Cheung, Michael Gulrajani, Sarah E. M. Herman, Christopher Pleyer, Inhye E. Ahn, Maryalice Stetler-Stevenson, Constance M. Yuan, Irina Maric, Erika M. Gaglione, Hailey M. Harris, Stefania Pittaluga, Min Hui Wang, Priti Patel, Mohammed Z. H. Farooqui, Raquel Izumi, Ahmed Hamdy, Todd Covey, Adrian Wiestner
Journal: Blood
Blood (2020) 136 (1): 93–105.
https://doi.org/10.1182/blood.2019003715
Published: 2020
Includes: Supplemental data
Journal Articles

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

Clinical Trials & Observations
John C. Byrd, William G. Wierda, Anna Schuh, Stephen Devereux, Jorge M. Chaves, Jennifer R. Brown, Peter Hillmen, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline Barrientos, John M. Pagel, Jennifer A. Woyach, Kathleen Burke, Todd Covey, Michael Gulrajani, Ahmed Hamdy, Raquel Izumi, Melanie M. Frigault, Priti Patel, Wayne Rothbaum, Min Hui Wang, Susan O’Brien, Richard R. Furman
Journal: Blood
Blood (2020) 135 (15): 1204–1213.
https://doi.org/10.1182/blood.2018884940
Published: 2020
Includes: Supplemental data
Journal Articles

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Mark Roschewski, MD, Raquel Izumi, PhD, Ahmed Hamdy, MD, Manish R. Patel, MD, Hendrik-Tobias Arkenau, MD PhD, Sven de Vos, MD PhD, Patrick M Reagan, MD, Pier Luigi Zinzani, MD PhD, Andrew Davies, MD PhD, John M Pagel, MD PhD, Julie M Vose, MDMBA, Bojena Bitman, Graham Brock, PhD, Edwin Clark, PhD, Melanie M. Frigault, PhD, Joseph Ware, PhD, Buyue Yang, MD PhD, Wyndham Wilson, MD, Louis Staudt, MD, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2869.
https://doi.org/10.1182/blood-2019-125939
Published: 2019
Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

Richard R. Furman, MD, William G. Wierda, MD PhD, Anna Schuh, Stephen Devereux, PhD, Jorge M. Chaves, MD, Jennifer R. Brown, MD PhD, Peter Hillmen, MD PhD, Peter Martin, FRCPC, MD MS, Farrukh T Awan, MD, Deborah M. Stephens, DO, Paolo Ghia, MD PhD, Jacqueline C. Barrientos, MD MS, John M. Pagel, MD PhD DSc, Jennifer Woyach, MD, Kathleen Burke, PhD, Todd Covey, Michael Gulrajani, Ahmed Hamdy, MD, Raquel Izumi, PhD, Melanie M. Frigault, PhD, Priti Patel, MD, Wayne Rothbaum, Min Hui Wang, PhD, Susan M. O'Brien, MD, John C. Byrd, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3039.
https://doi.org/10.1182/blood-2019-128706
Published: 2019
Journal Articles

Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study

John C. Byrd, MD, Jennifer A. Woyach, MD, Richard R. Furman, MD, Peter Martin, FRCPC, MD MS, Susan M. O'Brien, MD, Jennifer R. Brown, MD PhD, Deborah M. Stephens, Jacqueline C. Barrientos, MD, Stephen Devereux, PhD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, John M. Pagel, MD PhD, Dih-Yih Chen, MD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Priti Patel, MD, Min Hui Wang, PhD, Nitin Jain, MD, William G. Wierda, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 692.
https://doi.org/10.1182/blood-2018-99-110451
Published: 2018
Journal Articles

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Clare C. Sun, MD, Pia Nierman, RN, Inhye E. Ahn, MD, Janet Valdez, Jennifer Lotter, Susan Soto, Sarah E. M. Herman, PhD, Todd Covey, PhD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Dongmei Liu, PhD, Priti Patel, MD, Adrian Wiestner, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4424.
https://doi.org/10.1182/blood-2018-99-110395
Published: 2018
Journal Articles

Partial Reconstitution of Humoral and Cellular Immunity in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib

Christopher Pleyer, MD, Clare C. Sun, MD, Pia Niermann, Xin Tian, Inhye E. Ahn, MD, Janet Valdez, Jennifer Lotter, Raquel Izumi, PhD, Ahmed Hamdy, MD, Adrian Wiestner, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1874.
https://doi.org/10.1182/blood-2018-99-111919
Published: 2018
Journal Articles

Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia: The Phase 1b/2 ACE-CL-003 Study

Jennifer A. Woyach, MD, Farrukh T. Awan, MD MS, Mojgan Jianfar, MD, Kerry A. Rogers, MD, Jeffrey Jones, MD MPH, Todd Covey, PhD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Priti Patel, MD, Min Hui Wang, PhD, John C. Byrd, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 432.
https://doi.org/10.1182/blood.V130.Suppl_1.432.432
Published: 2017
Journal Articles

Combined Inhibition of mTOR and BTK Signaling Is Required for Optimal Long Term Growth Inhibition in DLBCL Models

Wolfram Brugger, MD, Maureen Hattersley, PhD, Alexandra Bussey, PhD, Corinne Reimer, PhD, Adriana E. Tron, PhD, Anna Staniszewska, PhD, Oona Delpuech, PhD, Larissa Carnevalli, PhD, Cecile M. Krejsa, PhD, Michele Mayo, PhD, Lynne Neveras, PhD, Maryann San Martin, PhD, Abla Rideout, PhD, Theresa Proia, PhD, Brandon Willis, PhD, J. Elizabeth Pease, PhD, Ahmed Hamdy, MD, Sabina C. Cosulich, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4113.
https://doi.org/10.1182/blood.V130.Suppl_1.4113.4113
Published: 2017
Journal Articles

Pooled Analysis of Safety Data from Clinical Trials Evaluating Acalabrutinib Monotherapy in Hematologic Malignancies

John C. Byrd, MD, Roger Owen, MD, Susan M. O'Brien, MD, Jennifer R. Brown, MD PhD, Peter Hillmen, MBChB, PhD, Bojena Bitman, Nataliya Chernyukhin, MD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Priti Patel, MD, Liat Schwartz-Sagi, MD, Edwin Tucker, MD, Nathan H. Fowler, MD, Matthew J. Streetly, BMBS, PhD MRCP, FRCPath, Adrian Wiestner, MD, Simon Rule, MD, Michael Wang, BS
Journal: Blood
Blood (2017) 130 (Supplement 1): 4326.
https://doi.org/10.1182/blood.V130.Suppl_1.4326.4326
Published: 2017
Journal Articles

CYP3A-Mediated Drug Interaction Profile of Bruton Tyrosine Kinase Inhibitor, Acalabrutinib

Raquel Izumi, PhD, Paul G. Pearson, PhD, Ahmed Hamdy, MD, Sara Rodriquez, MHA, Yolanda Y.L. Yang, MD PhD, Roger G. Ulrich, PhD, Terry Podoll, PhD, Marilee Andrew, PhD, Cecile M. Krejsa, PhD, Tim Ingallinera, BSc, J. Greg Slatter, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4996.
https://doi.org/10.1182/blood.V130.Suppl_1.4996.4996
Published: 2017